{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Designated
Source:
FDA ORPHAN DRUG:939923
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:910122
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:876122
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:904922
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:884922
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
ZLN005 was developed as a novel small molecule, led to changes in peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) mRNA levels, glucose uptake, and fatty acid oxidation in L6 myotubes. ZLN005 exerted promising therapeutic effects for treating type 2 diabetes. ZLN005 increases fat oxidation and improves the glucose tolerance, pyruvate tolerance, and insulin sensitivity of diabetic db/db mice. In addition, was confirmed potential of PGC-1α as a drug target for the treatment of type 2 diabetes mellitus (T2DM) and metabolic syndromes.
Status:
Designated
Source:
FDA ORPHAN DRUG:627218
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:627218
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:627218
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:627218
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:803720
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
